KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeMD (LFMD) Research & Development (2019 - 2025)

LifeMD (LFMD) has disclosed Research & Development for 7 consecutive years, with -$920045.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 276.07% year-over-year to -$920045.0, compared with a TTM value of $7.3 million through Dec 2025, up 7.13%, and an annual FY2025 reading of $7.3 million, up 7.13% over the prior year.
  • Research & Development was -$920045.0 for Q4 2025 at LifeMD, down from $2.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $2.8 million in Q3 2025 and bottomed at -$920045.0 in Q4 2025.
  • Average Research & Development over 5 years is $1.2 million, with a median of $1.1 million recorded in 2022.
  • The sharpest move saw Research & Development skyrocketed 1443.77% in 2022, then tumbled 276.07% in 2025.
  • Year by year, Research & Development stood at $294169.0 in 2021, then skyrocketed by 246.45% to $1.0 million in 2022, then surged by 96.04% to $2.0 million in 2023, then tumbled by 112.24% to -$244650.0 in 2024, then crashed by 276.07% to -$920045.0 in 2025.
  • Business Quant data shows Research & Development for LFMD at -$920045.0 in Q4 2025, $2.8 million in Q3 2025, and $2.7 million in Q2 2025.